Additionally, PI3KCA mutations cause ALK TKI resistance in NSCLC [79,98,132,146], and lorlatinib resistance of ALCL xenografts has been associated with PI3K/Akt pathway upregulation [124]. The gene discussed is AKT1; the disease is anaplastic large cell lymphoma.